<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121005">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01888471</url>
  </required_header>
  <id_info>
    <org_study_id>V98_22OB</org_study_id>
    <nct_id>NCT01888471</nct_id>
  </id_info>
  <brief_title>Feasibility Study Identifying Antibody Levels Associated With Reduced Risk of Invasive Group B Streptococcus Disease in Young Infants.</brief_title>
  <official_title>Feasibility Study for Identifying a Sero-correlate of Protection Against Invasive Group B Streptococcus Disease in Newborns and Young Infants Aged Less Than 90 Days.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>South African: South African Medicines Control Council</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Feasibility phase for a study to evaluate antibody levels against Group B Streptococcus in
      mothers and their infants at delivery to establish antibody levels associated with
      reductions in risk of GBS disease in infants aged less than 90 days.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Enrolment rates</measure>
    <time_frame>Throughout the study</time_frame>
    <safety_issue>No</safety_issue>
    <description>To test key operational aspects of the proposed nested case control study to identify antibody levels associated with reduced risk of GBS disease in infants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Completeness of clinical data collection</measure>
    <time_frame>Throughout the study</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Proposition maternal-infant dyads with maternal and cord collected.</measure>
    <time_frame>Throughout the study</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>GBS serotype distribution in subjects vaginally colonized with GBS at delivery.</measure>
    <time_frame>Throughout the study</time_frame>
    <safety_issue>No</safety_issue>
    <description>Provide baseline population data on maternal GBS serotype distribution and anticapsular antibody levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of GBS anticapsular antibody concentrations (ser in subjects vaginally colonized with GBS at delivery.</measure>
    <time_frame>Throughout the study</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Invasive Group B Streptococcus Disease</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>Infants with culture confirmed GBS disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Infants born to GBS colonized mother who do not develop GBS disease</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Maternal and cord serum aliquots will be retained.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women aged 18 years or older attending for antenatal care or delivery at 1
        academic hospital centers in the Johannesburg area and the antenatal clinics serving that
        hospital centers.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        (i) Pregnant women attending antenatal clinic in one of the participating
        antenatal-clinics and/or delivering at one the participating delivery center.

        (ii) Subjects aged â‰¥18 years. (iii)  Able to understand and comply with planned study
        procedures. (iv) Provides written informed consent.

        Exclusion Criteria:

        (i) Refuses to consent to study participation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines and Diagnostics</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Drug Information Services</last_name>
    <phone>18002447668</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Respiratory and Meningeal Pathogen Research Unit</name>
      <address>
        <city>Soweto</city>
        <state>Gauteng</state>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shabir Madhi, Professor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 8, 2014</lastchanged_date>
  <firstreceived_date>June 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Feasibility</keyword>
  <keyword>Group B Streptococcus</keyword>
  <keyword>anti-capsular antibodies</keyword>
  <keyword>serotype specific</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
